Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.48 USD | +7.21% | +11.59% | +25.48% |
05-14 | Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating | MT |
05-14 | Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.48% | 492M | |
+28.47% | 49.18B | |
+0.84% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.78% | 26.09B | |
-22.26% | 18.71B | |
+7.87% | 13.26B | |
+32.37% | 12.32B | |
-0.45% | 11.99B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Sector Update: Health Care